logo
logo
Stevanato Group S.p.A.

Stevanato Group S.p.A.

NYSE•STVN
CEO: Mr. Franco Stevanato
セクター: Healthcare
業種: Medical - Instruments & Supplies
上場日: 2021-07-16
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.
連絡先情報
Via Molinella, 17, Piombino Dese, PD, 35017, Italy
39-04-99-31-811
www.stevanatogroup.com
時価総額
$4.37B
PER (TTM)
26.6
25.4
配当利回り
0.4%
52週高値
$28.00
52週安値
$13.91
52週レンジ
15%
順位29Top 17.8%
5.2
F-Score
改良版 Piotroski 分析
6年ファンダメンタル
堅調 • 5.2 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2020-2025

財務ダッシュボード

Q3 2025 データ

売上高

$354.39M+9.11%
直近4四半期の推移

EPS

$0.15+18.18%
直近4四半期の推移

フリーCF

-$1.36M-98.94%
直近4四半期の推移

2024 Annual 決算ハイライト

主なハイライト

Revenue Increased Slightly Total revenue reached €1,104.0 M, marking a 1.7% increase for the fiscal year ended December 31, 2024.
High-Value Solutions Growth High-value solutions revenue grew 15.3% to €422.3 M, increasing its share of total revenue to 38.3%.
Operating Cash Flow Improved Cash flow from operations improved by €50.6 M, reaching €155.8 M for the year.
Reduced Free Cash Flow Burn Free Cash Flow usage decreased by €185.4 M, resulting in a less negative FCF of (€148.5 M).

リスク要因

Profitability Margins Compressed Operating Profit fell 19.7% to €161.1 M due to significant gross profit margin compression across both segments.
Vial Destocking Impact Lower revenue from standard vials negatively impacted Biopharmaceutical segment gross margin by 4.2 percentage points.
Engineering Segment Revenue Decline Engineering segment revenue dropped sharply by 17.4%, totaling €170.3 M for the year.
Internal Control Material Weaknesses Material weaknesses identified in internal controls over financial reporting, particularly IT general controls, require ongoing remediation.

見通し

Focus on High-Value Mix Strategy centers on increasing high-value solutions mix to drive future revenue and profit growth.
Capacity Expansion Execution Continue executing expansion projects in US (Fishers) and Italy (Latina) facilities to meet demand.
Engineering Segment Optimization Execute Engineering optimization plan to right-size operational structure and harmonize industrial processes.
New Growth Financing Secured Secured new €20.0 M loan in February 2025 to support ongoing capital investments in growth platforms.

同業比較

売上高 (TTM)

Alcon Inc.ALC
$10.19B
+4.3%
ResMed Inc.RMD
$5.40B
+9.6%
Bausch + Lomb CorporationBLCO
$4.98B
+6.2%

粗利益率 (最新四半期)

Axsome Therapeutics, Inc.AXSM
93.0%
+1.1pp
AtriCure, Inc.ATRC
75.5%
+0.6pp
ResMed Inc.RMD
62.2%
+3.6pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
ALC$39.17B37.34.8%16.6%
RMD$36.86B24.924.8%11.8%
WST$18.02B36.717.4%0.0%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
0.2%
緩やかな成長
4四半期純利益CAGR
-6.5%
収益性の低下
キャッシュフロー安定性
100%
優れたキャッシュフローの実績

深度リサーチ

次回決算:2026年3月5日
|
EPS:$0.19
|
売上高:-
財務レポート
財務データ
全年度

  • Form 20-F - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年3月6日|
    売上高: $1.19B+1.7%
    |
    EPS: $0.47-21.8%
    予想を上回る

  • Form 20-F - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年3月7日|
    売上高: $1.17B+10.3%
    |
    EPS: $0.59+3.8%
    予想を上回る

  • Form 20-F - FY 2022

    会計期末: 2022年12月31日|提出日: 2023年3月2日|
    売上高: $1.17B+16.6%
    |
    EPS: $0.59+0.0%
    予想を下回る

  • Form 20-F/A - FY 2021

    会計期末: 2021年12月31日|提出日: 2022年4月5日|
    売上高: $1.17B+27.5%
    |
    EPS: $0.59+89.3%
    予想を下回る

  • Form 20-F - FY 2021

    会計期末: 2021年12月31日|提出日: 2022年3月8日|修正版データを参照